J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary Veridex will partner with Massachusetts General Hospital to help bring a next-generation cancer blood test to market, both institutions announced Jan. 3.
You may also be interested in...
J&J Highlights Late-Stage R&D Prospects Across Pharma Division
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.
Study Shows Circulating Tumor Cell Chips Track Cancer Drug Response
Circulating tumor cell chips show promise as monitors of cancer therapy response in a study led by the Massachusetts General Hospital Cancer Center published July 2 in the New England Journal of Medicine
Sliding Scale: Bar For COVID Therapeutics EUAs ‘Can Be Somewhat Variable’ – FDA’s Peter Marks
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.